Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.48 |
| ▸ | CDK2 | P24941 | 15/20 | 0.48 |
| ▸ | CCND1 | P24385 | 11/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 11/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576254 | 0.93 | MAPK14 (0.53) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL917150 | 0.91 | MAPK14 (0.53) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL3674368 | 0.91 | MAPK8 (0.53) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL916901 | 0.91 | MAPK14 (0.52) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL3580991 | 0.90 | MAPK14 (0.53) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL3679319 | 0.90 | MAPK14 (0.51) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL3682636 | 0.90 | MAPK14 (0.49) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL3677049 | 0.90 | MAPK14 (0.64) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL3675578 | 0.90 | MAPK14 (0.52) | MAPK14LCKCCNE1CDK2CCND1 | |
| SCHEMBL916228 | 0.89 | MAPK14 (0.59) | MAPK14LCKCCNE1CDK2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-02-04 | — | — | US | disclosed |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| EP-2066661-A2 | PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-06-10 | — | — | EP | disclosed |
| EP-1958947-A1 | Inhibitors of phosphodiesterase type 4 | Ranbaxy Laboratories Limited (IN) | 2008-08-20 | — | — | EP | disclosed |
| EP-1948164-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008035316-A2 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007045979-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | ADRB2, ADRB1, ADRA2C | MAPK14 238/4885LCK 348/4885CCNE1 4437/4885 |
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | MAPK14 1715/4885LCK 910/4885CCNE1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.